

# Idea Award - Request for Proposals (RFP)

Institute for Follicular Lymphoma Innovation (IFLI)

Moonshot Initiative

Letter of Intent (LOI) due: 18 Sept 2023

---

The LOI template is available at <https://i-fli.org/>

---

## Moonshot Initiative

The goal of IFLI's Moonshot Initiative is to unravel the pathogenesis of Follicular Lymphoma (FL) with a particular focus on:

- i. Common/clonal precursor cell(s) (CPCs)
- ii. Lymphoma microenvironment (LME)
- iii. Epigenetics and cell states

To launch the Moonshot Initiative, IFLI assembled a Moonshot Team, primarily physicians and scientists with expertise in the early biology of FL, as well as some with clinical expertise in FL.

Through the Moonshot Initiative, IFLI is committed to sponsoring a series of awards via RFPs, starting with the **Idea Award**.

Please also refer to the **Moonshot Initiative Investigator Brief** on the IFLI website <https://i-fli.org/>

**Idea Awards** are for two years, \$250K/year direct costs and 10% allowable indirect costs. Idea Award recipients will be evaluated for milestones at one year.

Assuming milestones are met by the end of the 2-year funding period, and the foundation finds that the research program has scientific merit, then the investigator will be invited to submit a second proposal for the possibility of a 3-year award extension of \$500k/year direct costs and 10% allowable indirect costs.

### Application Process:

The LOI template is available at <https://i-fli.org/> and can be downloaded, completed, and submitted by email to [awards@i-fli.org](mailto:awards@i-fli.org) by 18 September 2023.

- The Idea award is designed to support the identification and understanding of the biologic potential and clonal evolution of precursor cells in FL.
- Applicants are encouraged to think about novel and/or disruptive ideas for addressing these issues from a genetic, epigenetic, and/or immunologic standpoint.
- All early-pathogenesis, pre-clinical research designs will be considered.
- Applications focused on biomarker validation of large cohorts and/or clinical trials will not be considered.
- Applicants with studies that will generate large-scale human genomic data will be expected to describe a genomic data sharing plan.

#### Review Process:

The Moonshot Team will be instrumental in conducting the review process for the 2-page letters of intent and 6-page full proposals submitted for IFLI's awards. Additional scientific expertise will be recruited proposals as needed (eg, experts in AI/machine learning). Any member of the Moonshot Team who is involved in one or more submissions of an Idea Award application will be recused from the review process.

#### Eligibility Criteria for all IFLI awards:

- Applications will be accepted for review from all regions, globally. Certain legal restrictions for funding may apply by region.
- All data will be generated according to a Moonshot Initiative data generation plan to be shared with FL research groups
- All data from the same genre will be harmonized to facilitate universal access
- Authorship and IP rules will be defined and agreed upon before engaging with each partner

### **Sponsored Research Agreement**

IFLI and awardee recipient shall sign a mutually agreed upon Sponsored Research Agreement to memorialize the terms of the Program and the obligations of each Party. Provisions in such Sponsored Research Agreement shall include, but not be limited to the following in 1-5 below.

1. **Research Program Conduct and Reporting:** Research funding recipient ("Recipient") will diligently execute the funded research program (the "Program"), will keep IFLI reasonably informed of research progress, and will provide at least interim and final reports summarizing Program data and results;
2. **Data Ownership and Research Use:** Recipient owns the Program data and results and grants to IFLI a nonexclusive, royalty-free, sub-licensable license to Program data and results for research purposes;
3. **Data sharing:** Recipient will promptly make Program data available, at least in accordance with NIH data sharing guidelines, and will deposit Program data in to-be-specified shared database(s) to ensure access and use by the scientific research community;
4. **Publication:** As scientifically appropriate, Recipient will promptly seek to disseminate Program results through peer-reviewed publications and presentations;
5. **Inventions:** (i) Recipient will diligently disclose and seek to protect (such as through patenting) any inventions resulting from the Program ("Inventions"); (ii) Recipient will diligently seek a licensee or licensees to develop and commercialize Inventions; and (iii) Recipient will provide IFLI with a share of Recipient's revenues (such as milestones and royalties, excluding research funding) that Recipient receives from licensing Inventions, which will be equitably proportioned based on IFLI's and Recipient's respective contributions to the Invention(s).

## Timeline

18 Sept 2023	Letter of Intent (LOI) due from applicants
29 Sept 2023	IFLI notifications of acceptance and full application template sent by email to selected applicants
1 Dec 2023	Full application due
15 Feb 2023	IFLI notifications of acceptance sent by email to awardees
15 Aug 2023	Deadline for starting project

The LOI template is available at <https://i-fli.org/>

\*NB: Notwithstanding anything to the contrary, this RFP is for informational purposes only and is nonbinding. IFLI reserves the right to change any program requirements and/or program elements at its sole discretion.

## About IFLI

The Institute for Follicular Lymphoma Innovation (IFLI) is dedicated to supporting advances in understanding the biology of follicular lymphoma (FL) and transformed FL (tFL) to accelerate the development of innovative treatment options, extend the life expectancy of people with follicular lymphoma and ultimately develop a cure.

IFLI aims to promote data sharing among researchers and institutions working on different aspects of FL research, fostering collaboration and enabling the exchange of knowledge and expertise.

The objectives of IFLI are:

1. **Improve the understanding of the pathogenesis of FL:** Identify the molecular mechanisms and pathways that drive the development and progression of FL, including the genetic and epigenetic changes that occur in FL cells and elucidate how these complex factors work together within the lymphoma microenvironment (LME).
2. **Develop new diagnostic and prognostic biomarkers:** Accurately identify FL patients who are at risk of early disease progression, histological transformation, or relapse.
3. **Identify new therapeutic targets:** Develop more effective treatment options for patients at higher risk of progression.
4. **Accelerate clinical trials:** Advance clinical research for FL by facilitating collaboration between researchers, KOLs, and industry partners.

IFLI is supporting a variety of initiatives through awards and partnerships to accomplish these objectives over the next ten years. Moonshot is one of these initiatives, launched in June 2023.